CV Risk Estimation vs COAPT Risk Score

This app is for CLINICIANS, not the lay public. The CV Risk app presents clinicians with three valuable 10-year cardiovascular event risk calculators to serve clinicians and learners in primary prevention of cardiovascular disease. It is for clinicians only, not the lay public. The calculators are Framingham 2008, ASCVD 2013, and the revised pooled cohort equations ASCVD of 2018. The app addresses such common questions as: • What is the ASCVD 10-year CV risk for a 57 year old male hypertensive smoker with a given set of lipid and blood pressure numbers? • What’s the magnitude of impact of a patient on their own improving their cholesterol by 11, 27, or 41 points? • For a poorly controlled hypertensive smoker with a 10-year risk of 31.3%, how impactful would improved blood pressure control or smoking cessation be? • How impactful is a cholesterol of 220 on a given patient's risk at 35 vs. 55 vs. 75 years old? • I hear that ASCVD 2013 overestimates risk, particularly for black adults? True? What about the revised pooled cohort equations of 2018? The app explicitly does not include treatment thresholds, LDL targets, estimates of impact of therapy, coronary calcium scoring, etc. I wanted the cleanest simplest tool possible for evaluating and discussing cardiovascular risk with all the other more subjective, controversial stuff out of the way. This app is written and intended for practicing clinicians like internists and family physicians; for resident physician trainees; for medical students; and of course for other clinician colleagues like NP's and PA's. Cardiologists could use this app, but you folks are focused on secondary prevention, which is an entirely different ballgame. As an educator and clinician, I am interested in feedback and I would be grateful for guidance on improving the tool.

For educational purposes and for use by medical professionals only. For patients with severe functional mitral regurgitation and symptomatic heart failure (left ventricular ejection fraction between 20-50%) despite best medical therapy. The COAPT Risk Score is a simple risk prediction tool created by combining clinical and echocardiographic variables in patients with heart failure (HF) and moderate-to-severe or severe functional mitral regurgitation (FMR) who remain symptomatic despite maximally tolerated guideline directed medical therapy (GDMT). The COAPT Risk Score provides valuable prognostic information regarding the 2-year risk of death and/or heart failure hospitalization (HFH). The score is derived from the COAPT trial population of patients with HF and moderate-to-severe or severe FMR randomized to treatment with either transcatheter edge-to-edge repair (TEER) with MitraClip plus GDMT or GDMT alone. We can incorporate TEER in the risk score and provide updated 2-year risk of death and/or HFH which can serve as a valuable shared decision-making tool for patients and physicians as well as heart teams while deciding about TEER. Created by a team of subject-matter experts including: the director of The Mount Sinai Hospital cardiac cath lab Dr. Kini, Director of Clinical and Interventional Cardiology at the Mount Sinai Health System Dr Sharma, the Mount Sinai Hospital Surgical Director Dr. Tang, COAPT Principal Investigator Dr. Stone, and COAPT Risk Score publication author Dr. Shah.